Scientists develop gel that delivers drugs directly to diseased joints

Osteoarthritis (OA) is a progressive condition affecting the lives of more than 32 million Americans. U.S. National Science Foundation-funded researchers based at NYU, including NYU Tandon Professor Jin Kim Montclare, identified the molecular mechanism and therapeutic payload for delivering pharmacologic treatment directly to affected joints, effectively halting the onset and progression of post-traumatic osteoarthritis. "We have developed a unique protein-based gel capable of minimally invasive, sustained delivery of prospective therapeutics in OA," said Montclare.